CONFERENCE PROGRAM
(Updated as of September 29, 2022)

TUESDAY, SEPTEMBER 27, 2022
3:00 pm  Registration Opens (3:00-7:00 pm, West Promenade)

WEDNESDAY, SEPTEMBER 28, 2022

7:00 am    Breakfast (7:00-8:00 am, West Promenade)

8:00 am    Welcome
Margaret Foti, American Association for Cancer Research, Philadelphia, Pennsylvania
Jill O’Donnell-Tormey, Cancer Research Institute, New York, New York

8:15 am    Keynote Address
Crystal L. Mackall, Stanford Center for Cancer Cell Therapy, Stanford University School of Medicine,
Stanford, California
Expanding the reach of CAR T cell therapy for cancer

9:00 am-12:30 pm
Session 1:  T Cell Failure in Cancer Immunotherapy (including Tumor-Immune Metabolic Interactions)
Session Chair: Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York

9:00 am    Andrea Schietinger
CD8 T cell fate decisions in cancer and autoimmunity

9:30 am    Giovanni Galletti, University of California, San Diego, La Jolla, California
TGF-β inhibits the function of progenitor-exhausted CD8+ T cells in response to PD-1 blockade*

9:45 am    James Reading, University College London, Cancer Institute, London, United Kingdom
Circulating Tex cells track non-small cell lung cancer evolution and predict response to immunotherapy*

10:00 am   Benjamin Youngblood, St. Jude Children’s Research Hospital, Memphis, Tennessee
Epigenetic programs regulating CD8 T cell responses during immunotherapy

10:30 am   Daniela Thommen, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Dissecting and modulating reactive anti-tumor immunity in human cancers

11:00 am   Refreshment Break (11:00-11:30 am, Americas Halls I & II)

11:30 am   Dario A. Vignali, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
LAG-3: The third checkpoint inhibitor

12:00 pm   Ansuman Satpathy, Stanford University School of Medicine, Gladstone Institute for Genomic
Immunology, Stanford, California
High-throughput genomics in cancer immunotherapy
12:30 pm  LUNCH AND EXHIBITS (12:30-2:00 pm, Americas Halls I & II)

2:00-2:30 pm
William B. Coley Lecture
2:00 pm  Feng Shao, National Institute of Biological Sciences, Beijing, China
Pyroptosis: From antibacterial immunity to antitumor immunity

2:30-6:00 pm
Session 2: Yin and Yang of Tumor Microenvironment (part 1): Suppressing Antitumor Response
Session Chair: Mario Paolo Colombo, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

2:30 pm  Mario Paolo Colombo
Immune function of extracellular matrix in tumor microenvironment and bone marrow

3:00 pm  Ellen Puré, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania
Stromal cells and matrix direct immune cell trafficking and function in the microenvironment of pancreatic cancer

3:30 pm  Malay Haldar, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Novel subsets of tumor-promoting macrophages

4:00 pm  Arja Ray, University of California, San Francisco, San Francisco, California
Critical role of macrophages in organizing adaptive immunity against tumors*

4:15 pm  Refreshment Break (4:15-4:45 pm, Americas Halls I & II)

4:45 pm  Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
Neutrophils as drivers of metastasis - generation and function

5:15 pm  Santosha Vardhana, Memorial Sloan Kettering Cancer Center, New York, New York
Context-dependent regulation of T-cell exhaustion by extracellular nutrient availability

5:45 pm  Marine Fidelle, INSERM, Gustave Roussy Cancer Campus, Villejuif, France
Antibiotics disrupt the ileal MAdCAM-1/α4β7 axis, compromising tumor immunosurveillance during PD-1 blockade*

6:30 pm  Welcome Reception (6:30-8:30 pm, Americas Halls I & II)
THURSDAY, SEPTEMBER 29, 2022

7:30 am  Breakfast (7:30-8:30 am, West Promenade)

8:30 am-12:00 pm
Session 3: Yin and Yang of Tumor Microenvironment (part 2): Enhancing Antitumor Response
Session Chair: James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, Texas

8:30 am  Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York
Molecular and spatial correlates of response to PD-1 blockade in human tumors

9:00 am  Stefani Spranger, MIT, Cambridge, Massachusetts
Not all anti-tumor T cell responses are equal: Why dendritic cells matter

9:30 am  Brian Ruffell, Moffitt Cancer Center, Tampa, Florida
Therapeutic targeting of intratumoral dendritic cells

10:00 am  Tullia C. Bruno, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Harnessing B cell and tertiary lymphoid structure function in ovarian cancer for improved anti-tumor immunity

10:30 am  Refreshment Break (10:30-11:00 am, Americas Halls I & II)

11:00 am  Ilkka Pietilä, Uppsala University, Uppsala, Sweden
Mechanisms regulating tertiary lymphoid structures in the CNS*

11:15 am  Min-Hee Oh, Yale University, New Haven, Connecticut
Identifying the role of tRNA modifications in T cells*

11:30 am  Aaron Ring, Yale School of Medicine, New Haven, Connecticut
Overcoming resistance to cytokine activity in the TME

12:00 pm  LUNCH and POSTER SESSION A and EXHIBITS (12:00-2:00 pm, Americas Halls I & II)

2:00-3:45 pm
Session 4: The Immunology of Lesional Heterogeneity of Minimal Residual Disease
Session Chair: Guido Kroemer, Centre de Recherche des Cordeliers, Paris, France

2:00 pm  Brian Topp, Merck, Kenilworth, New Jersey
Lesion-to-lesion heterogeneity in response to Pembrolizumab treatment

2:30 pm  Matteo Gentili, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
ESCRT-dependent STING degradation curtails steady-state and cGAMP-induced signaling*

2:45 pm  James Ross, Emory University, Atlanta, Georgia
Role of XCR1+ dendritic cells in the generation and maintenance of stem like CD8 T cells*

3:00 pm  Jose M. Adrover, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
A vascular-restricted, tumor-induced neutrophil population drives vascular occlusion, pleomorphic necrosis, and metastasis*

3:15 pm  Valsamo Anagnostou, Johns Hopkins University School of Medicine, Baltimore, Maryland
Liquid biopsy approaches for monitoring immunotherapy response

3:45 pm  Refreshment Break (3:45-4:15 pm, Americas Halls I & II)
4:15-5:15 pm  
Session 5: Moderated Debate-Utility of Preclinical Models  
Moderator: Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York

4:15 pm  
**Mouse perspective:**  
Nikhil S. Joshi, Yale School of Medicine, New Haven, Connecticut  
Investigating mechanisms for maintaining functional immune responses in developing tumors  
Michelle Krogsgaard, Perlmutter Cancer Center at NYU School of Medicine, New York, New York  
Preclinical mouse models for T cell-based immunotherapies

**Clinical perspective:**  
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas  
From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy  
Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center, New York, New York  
Modeling immune response in ovarian cancer: opportunities and challenges

FRIDAY, SEPTEMBER 30, 2022

7:30 am  
**Breakfast** (7:30-8:30 am, West Promenade)

8:30 am-12:15 pm  
Session 6: Cellular Therapies: Engineering T cells  
Session Chair: Yvonne Y. Chen, University of California, Los Angeles, Los Angeles, California

8:30 am  
Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, New York, New York  
Immunogenic and therapeutic landscape of NRAS 61 public neoantigens

9:00 am  
Marcelo Vailati Negrao, The University of Texas MD Anderson Cancer Center, Houston, Texas  
Objective clinical response by KRAS mutation-specific TCR-T cell therapy in previously treated advanced non-small cell lung cancer*

9:15 am  
Johanna Olweus, University of Oslo, Oslo, Norway  
A TCR targeting a shared mutation mediates eradication of AML in vivo*

9:30 am  
Yvonne Y. Chen  
Engineering next-generation CAR-T cells for cancer immunotherapy

10:00 am  
Avery Posey, University of Pennsylvania, Philadelphia, Pennsylvania  
Leveraging tumor-associated alterations in O-glycosylation for cancer immunotherapy

10:30 am  
**Refreshment Break** (10:30-11:00 am, Americas Halls I & II)

11:00 am  
Ugur Sahin, BioNTech RNA Pharmaceuticals GmbH, Mainz, Germany  
In vivo augmented T cell therapies

11:30 am  
Jorge Mansilla-Soto, Memorial Sloan Kettering Cancer Center, New York, New York

12:00 pm  
Sam Saibil, Princess Margaret Cancer Centre, Toronto, Canada  
Amino acid starvation response enhances oxidative metabolism and T cell anti-tumor activity*

12:15 pm  
**LUNCH and POSTER SESSION B and EXHIBITS** (12:15-2:15 pm, Americas Halls I & II)
2:15-5:15 pm
Session 7: Embracing the Host Ecosystem or Ecology: Immune Health and Fitness
Session Chair: E. John Wherry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

2:15 pm  
E. John Wherry
Role of immune health in cancer immunotherapy and beyond: lessons from COVID-19

2:45 pm  
Jennifer Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas
Modulating the microbiome to promote health and end cancer

3:15 pm  
Laurence Zitvogel, Gustave Roussy, Paris, France
The gut checkpoint inhibitors

3:45 pm  
Refreshment Break (3:45-4:15 pm, Americas Halls I & II)

4:15 pm  
Shelley Herbrich, The University of Texas MD Anderson Cancer Center, Houston, Texas
Impact of Tet2-mutant clonal hematopoiesis on solid tumor immunology and response to checkpoint blockade*

4:30 pm  
Matthew H. Spitzer, University of California, San Francisco, Gladstone-UCSF Institute for Genomic Immunology, San Francisco, California
Systemic impacts of cancer on immune function

5:00 pm  
Jeremy Goc, Weill Cornell Medicine, New York, New York
Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer*

SATURDAY, OCTOBER 1, 2022

7:00 am  
Breakfast (7:00-8:00 am, West Promenade)

8:00-10:15 am
Session 8: Barriers and Opportunities for Tumor Vaccination
Session Chair: Ellen Puré, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania

8:00 am  
Vinod Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York
Individualized mRNA neoantigen vaccines for pancreatic cancer

8:30 am  
Sandra Demaria, Weill Cornell Medicine, New York, New York
Antigen presentation by irradiated cancer cells

9:00 am  
Justin Gibson, Genentech, South San Francisco, California
Identifying and overcoming barriers that limit the therapeutic anti-tumor efficacy of individualized RNA-lipoplex vaccines*

9:15 am  
Joshua Brody, Icahn School of Medicine at Mount Sinai, New York, New York
In situ vaccination: Large tumor regressions, off the shelf

9:45 am  
Ferry A. Ossendorp, Leiden University Medical Center, Leiden, The Netherlands
Self adjuvanted peptide-based cancer vaccines

10:15 am  
Refreshment Break (10:15-10:30 am, West Promenade)
10:30 am-1:00 pm
Session 9: Spatial, Temporal and Computational Approaches for Understanding Tumor Immunity
Session Chair: Robert D. Schreiber, Washington University in St. Louis, St. Louis, Missouri

10:30 am  Haydn T. Kissick, Emory University School of Medicine, Atlanta, Georgia
CD8 T-cell activation in cancer is comprised of two distinct phases.

11:00 pm  Benjamin G. Vincent, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Cancer immunogenomics research with the CRI iAtlas web portal

11:30 am  Ronald N. Germain, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Gaining Insight into Tumor Immunity By Combining New Highly Multiplex 2D and 3D Imaging with Analytical Tools

12:00 pm  Assaf Magen, Icahn School of Medicine at Mount Sinai, New York, New York
Intratumoral mregDC and CXCL13 T helper niches enable local differentiation of CD8 T cells following PD-1 blockade*

12:15 am  Robert D. Schreiber, Washington University in St. Louis, St. Louis, Missouri
Spatial-proteomics analysis of successful cancer immunotherapy in a mouse cancer model

12:45 pm  Closing Remarks

*Proffered presentations from selected abstracts